Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Larimar Therapeutics announced the publication of research demonstrating that treatment with their lead drug candidate, nomlabofusp, increases frataxin (FXN) levels in tissues relevant to Friedreich’s Ataxia (FA). These frataxin increases correlate between critical tissues and accessible peripheral tissues such as skin and buccal cells, supporting …